Legend Biotech Corp
At today's price, Legend Biotech Corp (LEGN) is priced for today's economics sustained for ~5.4 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- CARVYKTI, Legend's BCMA-directed CAR-T therapy for multiple myeloma partnered with Johnson & Johnson, drove net trade sales of about $597 million in the first quarter, up 62% on the year [Source: Legend Biotech Q1 2026 results, May 2026], and it is now most of the company. - Counter to the usual loss-making biotech setup, the price is a fairly contained bet: it asks for today's economics to hold for about 5.6 years, a duration the analysis rates within range, backed by $582.8M of net cash. - T
Is LEGN overvalued? See what's priced in →
184 institutional managers reported holding LEGN in 13F filings for the quarter ended 2026-03-31. Together they hold about 26% of the company; the top 10 hold 18%. 32 opened new positions that quarter. Held by FMR (Fidelity), HHLR Advisors (Hillhouse), BlackRock, among others. On the short side, 13.0M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (3.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
No open-market insider buys on file at LEGN over the trailing three years. Absence is a fact about the company, not a signal. 9 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
Last analyzed: July 19, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.